APPLICATION OF AN ANTIBODY TO PD-1 IN COMBINATION WITH FAMITINIB FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING TUMOURS Russian patent published in 2022 - IPC A61K39/395 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: presented are an application of an antibody to PD-1 in combination with famitinib for producing a medicinal product for treating tumours; a method for alleviating the adverse reaction caused by the antibody to PD-1 or an antigen-binding fragment thereof, including the administration of famitinib or a pharmacologically acceptable salt thereof in combination with the antibody to PD-1; a method for reducing the dose of the antibody to PD-11 or an antigen-binding fragment thereof or a dose of famitinib or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical kit for treating a tumour or a cancer, containing famitinib or a pharmaceutically acceptable salt thereof and the antibody to PD-1.

EFFECT: group of inventions allows for effective application of combinations of the above antibody with famitinib for treating cancerous tumours and alleviating the side reaction in the form of a reactive capillary hyperplasia, which may occur when the antibody to PD-1 is used separately.

23 cl, 4 tbl, 3 ex